par Bartsch, Rupert;Berghoff, Anna Sophie;Zielinski, Christoph;Gnant, Michael;Frings, Stefan;Marty, Michel;Awada, Ahmad ;Conte, PierFranco;Dickin, S.;Enzmann, Harald;Hasmann, Max;Hendriks, Hans H.R.;Llombart, Antonio;Massacesi, Cristian;Von Minckwitz, Gunter;Pénault-Llorca, Frederique;Scaltriti., Maurizio;Yarden, Yosef;Zwierzina, Heinz
Référence Annals of oncology, 25, 4, page (773-780), mdt531
Publication Publié, 2014
Référence Annals of oncology, 25, 4, page (773-780), mdt531
Publication Publié, 2014
Article révisé par les pairs
Titre: |
|
Auteur: | Bartsch, Rupert; Berghoff, Anna Sophie; Zielinski, Christoph; Gnant, Michael; Frings, Stefan; Marty, Michel; Awada, Ahmad; Conte, PierFranco; Dickin, S.; Enzmann, Harald; Hasmann, Max; Hendriks, Hans H.R.; Llombart, Antonio; Massacesi, Cristian; Von Minckwitz, Gunter; Pénault-Llorca, Frederique; Scaltriti., Maurizio; Yarden, Yosef; Zwierzina, Heinz |
Informations sur la publication: | Annals of oncology, 25, 4, page (773-780), mdt531 |
Statut de publication: | Publié, 2014 |
Sujet CREF: | Hématologie |
Cancérologie | |
Mots-clés: | Biological subtypes |
Breast cancer | |
HER2-positive disease | |
Luminal disease | |
Triple-negative disease | |
MeSH keywords: | Clinical Trials as Topic |
Female | |
Humans | |
Molecular Targeted Therapy | |
Receptor, ErbB-2 -- genetics | |
Signal Transduction | |
Triple Negative Breast Neoplasms -- classification -- genetics -- pathology -- therapy | |
Note générale: | SCOPUS: ar.j |
Langue: | Anglais |
Identificateurs: | urn:issn:0923-7534 |
info:doi/10.1093/annonc/mdt531 | |
info:pii/mdt531 | |
info:scp/84897035109 | |
info:pmid/24351401 |